Skip to main content

Formoterol Boosted Fat Burning Up to 25% in Study

A medicine used to treat asthma may also be a fat-burning drug, new research suggests.

When taken in pill form, the drug known as formoterol boosted fat burning while preserving protein metabolism, thus maintaining muscle mass, says researcher Paul Lee, MD, PhD, of the Garvan Institute of Medical Research and an endocrinologist at St. Vincent's Hospital in Sydney, Australia.

"Fat burning was increased up to 25%," he says of his study results. "But the amount of protein burned is less [than without the pill].''

That could be good news for people trying to shed fat and for people who have noticed an age-related decline in muscle mass, he says. "It can promote a loss of fat while preventing the inevitable loss of muscle," Lee tells WebMD.

Lee presented his findings Saturday at the Endocrine Society's annual meeting in Boston.

Two experts in obesity treatment who reviewed the findings say the research is promising. However, they also say the findings are preliminary and the study is small. The effects, if they bear out, might be more noticeable in the way clothes fit than in numbers on the scale, says Frank Greenway, MD, an obesity specialist at the Pennington Biomedical Research Center in Baton Route, La.

Formoterol is used as an inhaled medication for asthma and chronic obstructive pulmonary disease (COPD). Lee used it in pill form, giving eight men, on average 30 years old, 160 micrograms a day for one week.

Before and after the study, he measured the men's energy rates, fat oxidation, and whole body protein metabolism.

Each time, the measurements were taken after the men drank a standardized, high-carbohydrate liquid meal, Lee says.

"Comparing their before and after rate, their [overall] energy rate increased by more than 10%," he says. "Fat burning was up about 25%. But the amount of protein burned was less. The person burns less protein and more fat."

Theoretically, he says, an average person weighing 155 pounds could burn an extra 200 calories a day with the pill. Over time, that could translate to noticeable fat loss and maintained or gained muscle.

"If we lose more fat than muscle, that's a good thing," Lee says.

The inhaled form of the drug can cause an abnormally fast heartbeat, but Lee did not see this side effect in the men who took the pill form.

"Some had insomnia, but it was mild," he says. It was also temporary. "Some reported loss of appetite."

In addition to burning fat, the drug might prevent or treat muscle wasting that can accompany age. "It may potentially reverse or prevent this process and treat frailty," Lee says.

The National Health Medical Research Council Australia funded the study.
Asthma Drug as Fat-Burner Pill: Expert Weigh-In

Other drugs in this class have been looked at as fat burners, says Greenway, professor and chief of outpatient clinical research at Pennington.

"They do increase lean tissue and reduce body fat," he says of the drugs, in general. But he doesn't expect the weight loss results to be dramatic.

Reducing fat, however, should make people healthier, he tells WebMD. If the testing on the asthma drug bears out, he says, and it comes into use, "people would presumably look much better, but not tinier, if you will. If you get on the scale [after using the drug] you might not see a big difference."

''The report is certainly intriguing," says Bruce Wolfe, MD, president of the American Society for Metabolic and Bariatric Surgery and professor of surgery at Oregon Health and Science University, Portland.

However, he says, the increase Lee found in fat burning is modest. It would not take much to eat away the 200 or so extra calories burned with the pill, he says. "Eating a couple of cookies would do it."

However, over time, he says, taking the fat-burning pill could make a noticeable difference.

This study was presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.

SOURCES:

Endocrine Society annual meeting, Boston, June 4-7, 2011.

Comments

Popular posts from this blog

Final lunar eclipse of 2010 set for early morning of December 21

Skygazers hoping to catch the last lunar eclipse of 2010 on Tuesday morning best be ready to stay up late (or wake up very early) to watch the full moon as it goes through a range of dramatic color changes. The December 21 lunar eclipse is expected to last about three-and-a-half hours from its start as a partial eclipse at 1:33 a.m. ET to its finish at 5:01 a.m. ET, according to NASA. The previous lunar eclipse occurred June 26 . During a lunar eclipse, the moon, the Earth, and the sun align so that the sun's rays are shielded from the moon. An eclipse of the moon can only take place if the moon is full, and only if the moon passes through some portion of Earth's shadow, which is composed of two cone-shaped parts, one nested inside the other. The start of the total eclipse is expected around 2:41 a.m, when the entire moon passes through the Earth's umbra, or inner shadow, which blocks all direct sunlight from reaching the moon. The moon will tak...

Hand, Foot and Mouth Disease (HFMD) and Onychomadesis

  Introduction Nails are underutilized as diagnostic tools, despite being involved in many dermatologic conditions. This paper explores new concepts in the treatment of median nail dystrophy (MND), onychomycosis, and the nail pathology of hand, foot, and mouth disease (HFMD). A Pubmed database literature search was conducted for MND treatment, onychomycosis treatment, and HFMD nail pathology. Only papers published after January 2008 were reviewed. The results showed that 0.1% tacrolimus ointment can be an effective treatment for MND. Early studies on laser therapy indicate that it is a safe and efficacious treatment option for onychomycosis, compared to conventional oral antifungal agents. Vicks VapoRub (The Proctor & Gamble Company, Cincinnati, OH) is effective against onychomycosis and is a reasonable option in patients who choose to forgo conventional treatments. Lastly, there is evidence to support a correlation between HFMD and onychomadesis. ...

Men With Breast Cancer Face Worse Prognosis

Men who are diagnosed with breast cancer are more likely than female patients to die in the next 15 years, researchers report. "This may be due to a difference in tumor characteristics and treatment," says study leader Hui Miao, a PhD candidate at the National University of Singapore. Male breast cancer is rare, accounting for less than 1% of all breast cancers in the U.S. Given its scarcity, few studies have assessed its prognosis "and we know of no recent studies looking at trends in survival," Miao tells WebMD. So Miao and colleagues studied 459,846 women and 2,664 men diagnosed with breast cancer in Denmark, Finland, Switzerland, Norway, Singapore, and Sweden between 1970 and 2007. Among the findings, presented at the San Antonio Breast Cancer Symposium: Men were diagnosed at an older age: 69 vs. 61 for women. Twice as many men had later stage III or IV disease: 18% vs. 9% of women. Only 25% of men were alive 15 years after diagnosis, compared with 44...